LMP-744 is under clinical development by Gibson Oncology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LMP-744’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LMP-744 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LMP-744 overview

LMP-744 is under development for the treatment of relapsed solid tumors and lymphomas. It is administered through the intravenous route. The drug candidate is an indenoisoquinoline derivative. The drug candidate acts by targeting topoisomerase I.

Quick View LMP-744 LOA Data

Report Segments
  • Innovator
Drug Name
  • LMP-744
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Gibson Oncology
  • Originator: Purdue University
Highest Development Stage
  • Phase I

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.